Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Authors

Reid W. Merryman, Dana-Farber Cancer Institute
Natasha Edwin, Washington University School of Medicine in St. Louis
Amanda Cashen, Washington University School of Medicine in St. Louis
Nancy L. Bartlett, Washington University School of Medicine in St. Louis
Neha Mehta-Shah, Washington University School of Medicine in St. Louis
Armin Ghobadi, Washington University School of Medicine in St. Louis
Brad Kahl, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2020

Volume

4

Issue

5

First Page

858

Last Page

867

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2019001355.

Rights and Permissions

Reid W. Merryman, Natasha Edwin, Robert Redd, Jad Bsat, Matthew Chase, Ann LaCasce, Arnold Freedman, Caron Jacobson, David Fisher, Samuel Ng, Jennifer Crombie, Austin Kim, Oreofe Odejide, Matthew S. Davids, Jennifer R. Brown, Heather Jacene, Amanda Cashen, Nancy L. Bartlett, Neha Mehta-Shah, Armin Ghobadi, Brad Kahl, Robin Joyce, Philippe Armand, Eric Jacobsen; Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv 2020; 4 (5): 858–867. doi: https://doi.org/10.1182/bloodadvances.2019001355

Recommended Citation

Merryman, Reid W.; Edwin, Natasha; Cashen, Amanda; Bartlett, Nancy L.; Mehta-Shah, Neha; Ghobadi, Armin; Kahl, Brad; and al., et, "Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma." Blood Advances. 4, 5. 858 - 867. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/8884